Alterity Therapeutics (ATHE) EBITDA Margin (2016 - 2019)

Alterity Therapeutics' EBITDA Margin history runs 4 years deep, the most recent figure standing at 310.46% for Q4 2019.

• On a quarterly basis, EBITDA Margin fell 8780.0% year-over-year to 310.46% in Q4 2019; TTM through Dec 2019 was 546.62%, a 3269.0% increase from a year earlier, with the FY2024 full-year figure at 419.05%, changed N/A from the prior year.
• EBITDA Margin slipped to 310.46% in Q4 2019 per ATHE's latest filing, from 222.66% in the prior quarter.
• Across five years, EBITDA Margin topped out at 3178.13% in Q4 2017 and bottomed at 310.46% in Q4 2019.
• The 4-year median for EBITDA Margin is 215.68% (2018), against an average of 609.07%.
• Across the five-year window, EBITDA Margin jumped 338683 bps in 2017 and slumped 340079 bps in 2018, its largest moves.
• Year by year, EBITDA Margin stood at 208.71% in 2016, then soared by 1623 bps to 3178.13% in 2017, then plunged by 107 bps to 222.66% in 2018, then slumped by 39 bps to 310.46% in 2019.
• Per Business Quant, the three latest ATHE EBITDA Margin figures stand at 310.46% (Q4 2019), 222.66% (Q4 2018), and 3178.13% (Q4 2017).